Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18645
Title: Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron).
Authors: Ong, Sim Yee;Dolling, Lara;Dixon, Jeannette L;Nicoll, Amanda J;Gurrin, Lyle C;Wolthuizen, Michelle;Wood, Erica M;Anderson, Greg J;Ramm, Grant A;Allen, Katrina J;Olynyk, John K;Crawford, Darrell;Kava, Jennifer;Ramm, Louise E;Gow, Paul J;Durrant, Simon;Powell, Lawrie W;Delatycki, Martin B
Affiliation: Clinical Genetics, Austin Health, Heidelberg, Victoria, Australia
Bruce Lefroy Centre, Murdoch Childrens Research Institute, Parkville, Victoria, Australia
Department of Gastroenterology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Allergy and Immunology, Royal Children's Hospital, Parkville, Victoria, Australia
Gastro and Food Allergy, Murdoch Childrens Research Institute, Parkville, Victoria, Australia
Department of Gastroenterology, Eastern Health, Box Hill, Victoria, Australia
Bone Marrow Transplant and Haematology, Royal Brisbane Hospital, Herston, Queensland, Australia
RBWH Centre for the Advancement of Clinical Research, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia
Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Prahran, Victoria, Australia
Iron Metabolism Group, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
Hepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
Department of Gastroenterology, Fiona Stanley and Fremantle Hospitals, Murdoch, Western Australia, Australia
School of Medicine, University of Queensland, Herston, Queensland, Australia
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 12-Aug-2015
EDate: 2015
Citation: BMJ open 2015; 5(8): e008938
Abstract: HFE p.C282Y homozygosity is the most common cause of hereditary haemochromatosis. There is currently insufficient evidence to assess whether non-specific symptoms or hepatic injury in homozygotes with moderately elevated iron defined as a serum ferritin (SF) of 300-1000 µg/L are related to iron overload. As such the evidence for intervention in this group is lacking. We present here methods for a study that aims to evaluate whether non-specific symptoms and hepatic fibrosis markers improve with short-term normalisation of SF in p.C282Y homozygotes with moderate elevation of SF. Mi-iron is a prospective, multicentre, randomised patient-blinded trial conducted in three centres in Victoria and Queensland, Australia. Participants who are HFE p.C282Y homozygotes with SF levels between 300 and 1000 μg/L are recruited and randomised to either the treatment group or to the sham treatment group. Those in the treatment group have normalisation of SF by 3-weekly erythrocytapheresis while those in the sham treatment group have 3-weekly plasmapheresis and thus do not have normalisation of SF. Patients are blinded to all procedures. All outcome measures are administered prior to and following the course of treatment/sham treatment. Patient reported outcome measures are the Modified Fatigue Impact Scale (MFIS-primary outcome), Hospital Anxiety and Depression Scale (HADS), Medical Outcomes Study 36-item short form V.2 (SF36v2) and Arthritis Impact Measurement Scale 2 short form (AIMS2-SF). Liver injury and hepatic fibrosis are assessed with transient elastography (TE), Fibrometer and Hepascore, while oxidative stress is assessed by measurement of urine and serum F2-isoprostanes. This study has been approved by the Human Research Ethics Committees of Austin Health, Royal Melbourne Hospital and Royal Brisbane and Women's Hospital. Study findings will be disseminated through peer-reviewed publications and conference presentations. Trial identifier: NCT01631708; Registry: ClinicalTrials.gov.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18645
DOI: 10.1136/bmjopen-2015-008938
PubMed URL: 26270952
Type: Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Subjects: erythrocytapheresis
ferritin
haemochromatosis
phlebotomy
venesection
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.